This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Healthy
and you are
between 19 and 60
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a randomized, single-center, open-label, three-period, six-sequence, crossover, comparative study to evaluate the oral bioavailability of single doses of three vapendavir drug product formulations (the 264 mg free base tablet [test drug], 264 mg free base oral suspension [test drug], and two 132 mg phosphate salt capsules [reference drug]) in healthy volunteers. The study design consists of six dosing sequences. Each sequence comprises 3 periods and each subject is administered one of the three dosing formulations in the first period. A subject receives a different formulation in each of the subsequent periods, so that all subjects receive each formulation. The periods are separated by an approximate 7-day washout.

Provided treatments

  • Drug: vapendavir 132 mg capsule
  • Drug: vapendavir 264 mg tablet
  • Drug: vapendavir 24 mg/mL oral suspension

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02877264. The sponsor of the trial is Aviragen Therapeutics and it is looking for 48 volunteers for the current phase.
Official trial title:
A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers